Lecouvet F E, Dechambre S, Malghem J, Ferrant A, Vande Berg B C, Maldague B
Department of Radiology and Medical Imaging, UCL 10/2942, Saint Luc University Hospital, Université Catholique de Louvain, Hippocrate Ave., 10, B1200 Brussels, Belgium.
AJR Am J Roentgenol. 2001 Jan;176(1):91-6. doi: 10.2214/ajr.176.1.1760091.
This study in myeloma patients treated with myeloablative therapy and bone marrow transplantation assessed the prognostic value of MR imaging before and after treatment of the bone marrow and the prognostic value of an index reflecting changes on MR images obtained before and after treatment.
MR images (T1-weighted images before and after injection of gadolinium and T2(*)-weighted images) of the spine and pelvis were obtained 1 month before and 1 month after marrow transplantation in 25 consecutive patients with stage III myeloma. Pre- and posttreatment MR imaging patterns of marrow involvement (normal, focal, diffuse), number of focal lesions, and a "marrow evolution index" (0-8 on the basis of comparison of the lesions [number, size, contrast enhancement] and of the surrounding marrow background on pre- and posttreatment MR images) were determined. Hematologic and MR imaging parameters were correlated with the quality of response to treatment (complete versus partial remission) and with relapse-free and overall survival.
Response quality did not differ among categories of patients determined on the basis of MR images. Individual MR imaging parameters did not correlate with response duration and survival. Patients with a low marrow evolution index had significantly longer relapse-free (p < 10(-3)) and overall survival (p = 0.005) than patients with a high index.
Individual MR imaging parameters before and after treatment had no prognostic significance in our series of myeloma patients treated with marrow transplantation. Comparison of MR images before and after treatment using a marrow evolution index may help predict response duration and survival.
本研究对接受清髓性疗法和骨髓移植的骨髓瘤患者进行评估,以确定治疗前后骨髓磁共振成像(MR成像)的预后价值,以及反映治疗前后MR图像变化的一项指标的预后价值。
对25例连续的III期骨髓瘤患者在骨髓移植前1个月和移植后1个月获取脊柱和骨盆的MR图像(注射钆前后的T1加权图像以及T2*加权图像)。确定治疗前后骨髓受累的MR成像模式(正常、局灶性、弥漫性)、局灶性病变数量以及一个“骨髓演变指数”(基于治疗前后MR图像上病变[数量、大小、对比增强]及周围骨髓背景的比较,范围为0至8)。血液学和MR成像参数与治疗反应质量(完全缓解与部分缓解)、无复发生存率和总生存率相关。
基于MR图像确定的患者类别之间,反应质量并无差异。单个MR成像参数与反应持续时间和生存率无关。骨髓演变指数低的患者比指数高的患者无复发生存期显著更长(p < 10⁻³),总生存期也更长(p = 0.005)。
在我们这组接受骨髓移植的骨髓瘤患者中,治疗前后的单个MR成像参数无预后意义。使用骨髓演变指数比较治疗前后的MR图像可能有助于预测反应持续时间和生存率。